Fact

"To date, no pharmacological intervention has been approved for

Primary Ciliary Dyskinesia (PCD) indication

Source: https://pcdfoundation.org

~1/10000

Live births are affected by PCD

~95%

of patients develop bronchiectasis

~25%

of PCD patients experience life-threatening respiratory failure and require lung transplantation

0

approved treatment for PCD

Our goal

Bring an effective and evidence-based therapeutic solution specific for the treatment of Primary Ciliary Dyskinesia 

Welcome to

Cila Therapeutics

We are a clinic-ready stage, biotechnology company developing new inhaled therapies for the treatment of a rare genetic disorder, Primary Ciliary Dyskinesia or PCD.

About us

Our focus

Primary Ciliary Dyskinesia (PCD) is a rare and neglected disease. Patients experience chronic cough, respiratory problems, and recurrent ear and lung infections from birth onwards. Exacerbation of respiratory distress leads to frequent ER visits, hospitalization, poor quality of life for patients, and a huge economic burden. There is currently no pharmacological therapy approved specifically for the treatment of PCD. It is a critical and urgent medical need that must be addressed. 

Our programs

Our lead candidate is specifically designed to address acute symptoms and respiratory distress experienced by PCD patients. In the long term, it will also prevent recurrent infections, impede the lung damage and progression of the disease, and thus improve patients' quality of life.

We plan to further develop our portfolio with novel drug candidates dedicated to the treatment of other rare obstructive airway respiratory diseases such as Cystic Fibrosis (CF). We also plan to explore the therapeutic potential of our drug-candidate to address COVID-19 sequelae.

 

What is Primary Ciliary Dyskinesia (PCD)?

PCD is a rare disease caused by multiple genetic mutations involving fingerlike projections on airway cells known as "Cilia". It is estimated to affect ~1/10000 birth in the US.

 

Normal mucus traps pathogens and Cilia move to clear it. In PCD patients, due to genetic reasons, Cilia are dysfunctional so mucus builds up and forms "mucus plugs". These plugs clog airways and initiate a vicious cycle of recurrent infection, airway damage, permanent lung damage, and progression to bronchiectasis.

Source: NHLBI website 

Source: Mirra et al., 2017. Frontiers in Pediatrics. 

Symptoms

Patients experience chronic cough, respiratory problems, and recurrent ear and lung infections from birth onwards. A significant number of PCD cases experience life-threatening respiratory failure and some require lung transplantation. Exacerbation of respiratory distress leads to frequent ER visits, hospitalization, poor quality of life for patients, and a huge economic burden on families and the healthcare system. 

 
Our pipeline

We have a robust early-stage pipeline with both new chemical entities (NCE) and repurposed candidates

COMPOUND

DISCOVERY

INDICATION

PRECLINICAL

PHASE I

PHASE II

PHASE III

CIL-005

CIL-006

CIL-008 + CIL-005

CIL-009

CIL-010

PCD

Bronchiectasis

CF

PCD

TBD

 
 
LINKS
CONTACT
SOCIAL
  • White LinkedIn Icon

© 2020 by Cila Therapeutics